Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Heron Therapeutics (HRTX)

Heron Therapeutics (HRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Heron Therapeutics: Q4 Earnings Snapshot

Heron Therapeutics: Q4 Earnings Snapshot

HRTX : 2.94 (+13.51%)
Heron Therapeutics: Q3 Earnings Snapshot

Heron Therapeutics: Q3 Earnings Snapshot

HRTX : 2.94 (+13.51%)
Heron Therapeutics: Q2 Earnings Snapshot

Heron Therapeutics: Q2 Earnings Snapshot

HRTX : 2.94 (+13.51%)
Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company focused on improving the lives of...

HRTX : 2.94 (+13.51%)
Heron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and...

HRTX : 2.94 (+13.51%)
Heron Therapeutics Announces Cost Reduction Plan and Restructuring

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and...

HRTX : 2.94 (+13.51%)
Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing...

HRTX : 2.94 (+13.51%)
Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing...

HRTX : 2.94 (+13.51%)
Heron Therapeutics: Q1 Earnings Snapshot

Heron Therapeutics: Q1 Earnings Snapshot

HRTX : 2.94 (+13.51%)
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (the "Company"), a commercial-stage biotechnology company focused on improving the lives of patients by...

HRTX : 2.94 (+13.51%)

Barchart Exclusives

2 'Strong Buy' Cannabis Stocks Set to Gain on Spending Bill Maneuvers
The U.S. cannabis market could be on the cusp of a critical growth catalyst, presenting ripe investment opportunities for those ready to navigate its unique risks. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar